Cannabis and Epilepsy: Peer-Reviewed Research Consensus
Overview
The research base for cannabis and epilepsy includes 210 peer-reviewed studies spanning 2003–2026. Of these, 50 provide strong evidence, including 11 meta-analyses and 4 randomized controlled trials. Key findings with strong support include: meta-analysis of 550 patients found cbd reduced seizures by ~20 percentage points in severe childhood epilepsies, and meta-analysis of pivotal trials found cbd has independent anti-seizure effects, though the benefit is amplified by interaction with clobazam. However, several findings remain debated, and the evidence is not uniform across all areas. Many studies have methodological limitations including small sample sizes, short follow-up periods, and reliance on self-reported data.
What the Research Shows
Findings supported by multiple peer-reviewed studies. Stronger evidence means more consistency across study types.
Meta-analysis of 550 patients found CBD reduced seizures by ~20 percentage points in severe childhood epilepsies
Strong EvidenceMeta-analysis of pivotal trials found CBD has independent anti-seizure effects, though the benefit is amplified by interaction with clobazam
Strong EvidenceA meta-analysis of 4 RCTs confirmed CBD significantly reduces seizures both with and without clobazam, though the effect was somewhat larger with clobazam
Strong EvidenceWhere Scientists Disagree
Areas where research shows conflicting results or ongoing scientific debate.
Preclinical study showing whole cannabis extracts produced faster spasticity relief and more potent anticonvulsant effects than pure THC, with THC-free extracts also showing anticonvulsant activity
Moderate EvidenceReview identified five strategies for making cannabinoid medicines more effective while reducing psychoactive side effects, covering applications from pain to neurodegeneration
Moderate EvidenceSystematic review of 34 human studies found preliminary CBD benefits for anxiety, insomnia, and epilepsy, with complex THC interactions depending on delivery route
Moderate EvidenceExpert review found clinical evidence for cannabinoids in MS spasticity, refractory pain, and nausea, with emerging evidence for epilepsy, dystonia, tics, and other neurological conditions
Moderate EvidenceWhat We Still Don't Know
- Only 4 randomized controlled trials exist out of 210 studies — most evidence is observational or from reviews.
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Evidence Breakdown
Distribution of study types in this research area. Higher-tier evidence (meta-analyses, RCTs) provides stronger conclusions.
Key Studies
The most impactful research in this area.
Major meta-analysis of 152 RCTs finds cannabinoid effectiveness varies dramatically by specific drug and condition
By analyzing cannabinoid medications separately rather than lumping them together, this study reveals that the question "does cannabis work?" is misleading. The answer depends entirely on which cannabinoid and which condition.
Meta-analysis confirmed CBD reduces seizures by 33% in treatment-resistant epilepsy
This meta-analysis provides the strongest quantitative evidence to date supporting CBD as an add-on treatment for three of the most difficult-to-treat pediatric epilepsy syndromes.
CBD reduced seizures in both Dravet and Lennox-Gastaut syndromes, with enhanced effects when combined with clobazam
This meta-analysis directly addresses the critical question of whether CBD's seizure reduction is partly driven by its interaction with clobazam, showing CBD is effective in both clobazam users and the overall population, but more so in the combination.
CBD does have independent anti-seizure effects, though clobazam interaction boosts them
This addresses the critical question of whether CBD is truly anti-epileptic or merely boosting clobazam levels, concluding that both mechanisms contribute.
Meta-analysis of 4 RCTs confirms CBD reduces seizures with and without clobazam co-treatment
A persistent question has been whether CBD's seizure benefit depends on its interaction with clobazam rather than direct anticonvulsant effects. This meta-analysis demonstrates independent efficacy.
Meta-analysis confirms CBD reduces seizures in Dravet syndrome
Dravet syndrome is among the most severe drug-resistant epilepsies. This meta-analysis provides the highest level of evidence confirming that CBD offers meaningful seizure reduction for these patients.
Research Timeline
How our understanding of this topic has evolved.
2000–2009
2 studies published. Predominantly observational and review studies.
2010–2014
11 studies published. Includes 1 strong-evidence studies.
2015–2019
57 studies published. Includes 2 meta-analyses, 1 RCTs, 19 strong-evidence studies.
2020–present
140 studies published. Includes 9 meta-analyses, 3 RCTs, 30 strong-evidence studies.
About This Consensus
This consensus synthesizes 210 peer-reviewed studies: 11 meta-analyses (5%), 4 randomized controlled trials (2%), 22 observational studies (10%), 76 reviews (36%), 12 case studies (6%), 85 other study types (40%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
This page synthesizes findings from 210 peer-reviewed studies. It is not medical advice. Always consult a healthcare provider for personal health decisions.